GLUL Ablation Can Confer Drug Resistance to Cancer Cells via a Malate-Aspartate Shuttle-Mediated Mechanism

被引:13
|
作者
Muthu, Magesh [1 ]
Kumar, Ranjeet [1 ,3 ]
Khaja, Azharuddin Sajid Syed [1 ]
Gilthorpe, Jonathan D. [2 ]
Persson, Jenny L. [1 ]
Nordstrom, Anders [1 ]
机构
[1] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden
[2] Umea Univ, Dept Pharmacol & Clin Neurosci, S-90187 Umea, Sweden
[3] Rutgers State Univ, Publ Hlth Res Inst, New Jersey Med Sch, Rutgers Biomed & Hlth Sci, Newark, NJ 07103 USA
关键词
GLUL; NSCLC; drug resistance; metabolomics; glutamine; glycolysis; metabolism; targeted metabolomics; LC-MS; ACID GAMMA-MONOHYDROXAMATE; PROTEIN MRP GENE; MULTIDRUG-RESISTANCE; GLUTAMINE-SYNTHETASE; L1210; LEUKEMIA; EARLY MARKER; EXPRESSION; INHIBITION; METABOLISM; PAZOPANIB;
D O I
10.3390/cancers11121945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glutamate-ammonia ligase (GLUL) is important for acid-base homeostasis, ammonia detoxification, cell signaling, and proliferation. Here, we reported that GLUL ablation conferred resistance to several anticancer drugs in specific cancer cell lines while leaving other cell lines non-resistant to the same drugs. To understand the biochemical mechanics supporting this drug resistance, we compared drug-resistant GLUL knockout (KO) A549 non-small-cell lung carcinoma (NSCLC) cells with non-resistant GLUL KO H1299 NSCLC cells and found that the resistant A549 cells, to a larger extent, depended on exogenous glucose for proliferation. As GLUL activity is linked to the tricarboxylic acid (TCA) cycle via reversed glutaminolysis, we probed carbon flux through both glycolysis and TCA pathways by means of (13)C5 glutamine, (13)C5 glutamate, and (13)C6 glucose tracing. We observed increased labeling of malate and aspartate in A549 GLUL KO cells, whereas the non-resistant GLUL KO H1299 cells displayed decreased C-13-labeling. The malate and aspartate shuttle supported cellular NADH production and was associated with cellular metabolic fitness. Inhibition of the malate-aspartate shuttle with aminooxyacetic acid significantly impacted upon cell viability with an IC50 of 11.5 mu M in resistant GLUL KO A549 cells compared to 28 mu M in control A549 cells, linking resistance to the malate-aspartate shuttle. Additionally, rescuing GLUL expression in A549 KO cells increased drug sensitivity. We proposed a novel metabolic mechanism in cancer drug resistance where the increased capacity of the malate-aspartate shuttle increased metabolic fitness, thereby facilitating cancer cells to escape drug pressure.
引用
收藏
页数:20
相关论文
共 12 条
  • [1] C/EBPI3-LIP mediated activation of the malate-aspartate shuttle sensitizes cells to glycolysis inhibition
    Ackermann, Tobias
    Zuidhof, Hidde R.
    Mueller, Christine
    Kortman, Gertrud
    Rutten, Martijn G. S.
    Broekhuis, Mathilde J. C.
    Zaini, Mohamad Amr
    Hartleben, Gotz
    Calkhoven, Cornelis F.
    [J]. MOLECULAR METABOLISM, 2023, 72
  • [2] MDH1-mediated malate-aspartate NADH shuttle maintains the activity levels of fetal liver hematopoietic stem cells
    Gu, Hao
    Chen, Chiqi
    Hao, Xiaoxin
    Su, Ni
    Huang, Dan
    Zou, Yejun
    Lin, Shu-Hai
    Chen, Xianjun
    Zheng, Denghao
    Liu, Ligen
    Yu, Zhuo
    Xie, Li
    Zhang, Yaping
    He, Xiaoxiao
    Lai, Xiaoyun
    Zhang, Xiaocui
    Chen, Guo-Qiang
    Zhao, Yuzheng
    Yang, Yi
    Loscalzo, Joseph
    Zheng, Junke
    [J]. BLOOD, 2020, 136 (05) : 553 - 571
  • [3] A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
    Liu, Hailan
    Liu, Yang
    Zhang, Jian-Ting
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (02) : 263 - 270
  • [4] Expression of erbB3 upregulates Survivin via transcription independent mechanism in erbB2-overexpressing breast cancer cells to confer Paclitaxel resistance
    Wang, Shuiliang
    Huang, Xiaoping
    Lee, Choon-Kee
    Liu, Bolin
    [J]. CANCER RESEARCH, 2011, 71
  • [5] A Novel Drug Resistance Mechanism: Genetic Loss of Xeroderma Pigmentosum Complementation Group C (XPC) Enhances Glycolysis-Mediated Drug Resistance in DLD-1 Colon Cancer Cells
    Han, Yu
    Qu, Yuan Qing
    Mok, Simon Wing Fai
    Chen, Juan
    Xia, Cheng Lai
    He, Hu Qiang
    Li, Zheng
    Zhang, Wei
    Qiu, Cong Ling
    Liu, Liang
    Law, Betty Yuen Kwan
    Wong, Vincent Kam Wai
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [6] miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up -regulation of PTEN in colon cancer cells
    Shi, Xiaoxin
    Valizadeh, Amir
    Mir, Seyed Mostafa
    Asemi, Zatollah
    Karimian, Ansar
    Majidina, Maryam
    Safa, Amin
    Yosefi, Bahman
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 880
  • [7] Mechanism of resveratrol-mediated reversal of drug resistance of HL-60/ADR cells via PI3K/Akt/Nrf2 signaling pathway
    Shi, M.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1571 - 1571
  • [8] FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells
    Choi, Hae-Ji
    Jhe, Yoo-Lim
    Kim, Jungmin
    Lim, Ju Yeon
    Lee, Jae Eun
    Shin, Min-Kyue
    Cheong, Jae-Ho
    [J]. REDOX BIOLOGY, 2020, 36
  • [9] ATF2 translation is induced under chemotherapeutic drug-mediated cellular stress via an IRES-dependent mechanism in human hepatic cancer Bel7402 cells
    Li, Qi
    Gao, Wen-Qing
    Dai, Wen-Yan
    Yu, Chuang
    Zhu, Rui-Yu
    Jin, Jian
    [J]. ONCOLOGY LETTERS, 2016, 12 (06) : 4795 - 4802
  • [10] Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1
    Xie, Zheng-Yuan
    Wang, Fen-Fen
    Xiao, Zhi-Hua
    Liu, Si-Fu
    Tang, Sheng-Lan
    Lai, Yue-Liang
    [J]. JOURNAL OF BIOCHEMISTRY, 2020, 167 (06): : 557 - 564